FILE PHOTO: An employee of BioNTtech works at the “Area 100 R&D” research laboratory for personalised mRNA-based cancer vaccines at a new facility of BioNTech in Mainz, Germany, July 27, 2023. REUTERS/Wolfgang Rattay/File Photo
FILE PHOTO: An employee of BioNTtech works at the “Area 100 R&D” research laboratory for personalised mRNA-based cancer vaccines at a new facility of BioNTech in Mainz, Germany, July 27, 2023. REUTERS/Wolfgang Rattay/File Photo